English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

High on-treatment platelet reactivity (HTPR) on clopidogrel correlates with adverse clinical outcomes in patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI)1 . Whether HTPR on clopidogrel is a modifiable risk factor for ischemic events is not clear. We sought to evaluate the effect of the serial clopidogrel dose tailoring after platelet function testing (PFT) on a clinical outcome of the patients with determined HTPR after successful PCI in ACS. Patients and Methods: We screened 461 consecutive ACS patients. Exclusion criteria was present in 120 patients (continuous postinterventional glycoprotein (GP) IIbIIIa receptor inhibitor perfusion, thrombocytopenia ( 200 µmol/L), anemia (Htc 80 years of age). Patients without exclusion criteria (341) underwent PFT 1224 hours following PCI. Patients with determined HTPR on Proπireni saaeetak / Extended abstract

cardiologia croatica

Continuous clopidogrel dose modification after platelet function testing improves clinical outcome in acute coronary syndrome treated with percutaneous coronary intervention and initially determined high on-treatment platelet reactivity